Detail page

Knowledge Web

Person

Ute Hegenbart

Internistin

Name	Ute Hegenbart
Place	Deutschland
Gender	weiblich
Academic degree	apl. Prof. Dr. med. Oberärztin
Profession	Internistin (characteristic profession) Ärztin
Variant	U. Hegenbart
Related	Ludolf-Krehl-Klinik Hämatologie (Thema) Onkologie (Thema)
Record type	Person
GND-Identifier	1028373708
Record ID	1028373708
Involved in show all Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group Belantamab Mafodotin-assoziierte Keratopathie – eine häufige und therapiebeeinflussende Nebenwirkung Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis Cryo-EM reveals structural breaks in a patientderived amyloid fibril from systemic AL amyloidosis Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril Lokale und systemische Leichtkettenamyloidosen bei Patienten mit rheumatologischen Erkrankungen The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience Prognosis and Staging of AL Amyloidosis Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis AL amyloidosis with a localized B cell neoplasia A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis Deferred autologous stem cell transplantation in systemic AL amyloidosis Local vs. systemic pulmonary amyloidosis—impact on diagnostics and clinical management European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis Ursachen und Therapie der systemischen AA-Amyloidose Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Ute Hegenbart

Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

Belantamab Mafodotin-assoziierte Keratopathie – eine häufige und therapiebeeinflussende Nebenwirkung

Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis

Cryo-EM reveals structural breaks in a patientderived amyloid fibril from systemic AL amyloidosis

Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM

Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data

Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril

Lokale und systemische Leichtkettenamyloidosen bei Patienten mit rheumatologischen Erkrankungen

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience

Prognosis and Staging of AL Amyloidosis

Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis

Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril

A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis

Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis

AL amyloidosis with a localized B cell neoplasia

A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis

Deferred autologous stem cell transplantation in systemic AL amyloidosis

Local vs. systemic pulmonary amyloidosis—impact on diagnostics and clinical management

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis

Ursachen und Therapie der systemischen AA-Amyloidose

Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects